免疫比濁法試劑市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型、應用和地區細分，競爭情況，2020-2030 年

2024 年全球免疫比濁試劑市場價值為 54 億美元，預計在預測期內將實現令人印象深刻的成長，到 2030 年的複合年成長率為 6.10%。這種特殊類型的分析依賴濁度測定原理，可以測量溶液的濁度或混濁度。在免疫比濁法中，此方法用於定量測定患者血液樣本中的特定蛋白質或物質。此過程首先將患者的血清或血漿樣本引入含有針對目標蛋白質或分析物的特定抗體的試劑中。如果樣本中存在目標蛋白質，它就會與抗體結合，形成免疫複合物。這些複合物會使穿過溶液的光發生散射，導致濁度增加。濁度的變化與目標分析物的濃度成正比。免疫比濁法試劑是該過程的關鍵組成部分，因為它們含有形成免疫複合物所必需的特定抗體。

這些試劑經過精心配製，確保高特異性和靈敏度，可準確量化目標蛋白質。此外，它們的設計旨在最大限度地減少樣品中其他物質的干擾，確保結果精確可靠。免疫比濁法的主要優點之一是它廣泛適用於一系列分析物，包括 C 反應蛋白 (CRP)、免疫球蛋白和補體蛋白等蛋白質。這使得它成為臨床實驗室中評估各種疾病狀態和監測患者健康狀況的多功能工具。此外，免疫比濁法測定相對較快，能夠及時提供結果，這對於及時的臨床決策至關重要。此外，免疫比濁法可實現自動化，從而可以對患者樣本進行高通量分析。這提高了臨床實驗室的效率，使他們能夠在更短的時間內處理大量測試。免疫比濁法的自動化也減少了人為錯誤的可能性，進一步確保了結果的準確性和可靠性。

主要市場促進因素

慢性病和傳染病發生率上升

主要市場挑戰

自動化免疫化學產品採用率低

主要市場趨勢

自動化和高通量診斷系統的採用日益增多

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第5章：免疫比濁法試劑市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依類型（普通免疫比濁試劑、乳膠增強免疫比濁試劑）
  • 依應用分類（糖化血紅素、視黃醇結合蛋白、C 反應蛋白、抗鏈球菌溶血素「O」、類風濕因子、其他）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：北美免疫比濁法試劑市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 加拿大
  • 墨西哥

第7章：歐洲免疫比濁法試劑市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 英國
  • 義大利
  • 法國
  • 西班牙

第 8 章：亞太免疫比濁法試劑市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：南美洲免疫比濁法試劑市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲免疫比濁法試劑市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 合併與收購

第 13 章：全球免疫比濁法試劑市場：SWOT 分析

第 14 章：競爭格局

• Danaher Corporation
• Abbott Laboratories Inc
• Siemens Healthineers AG
• F. Hoffmann-La Roche AG
• DIALAB GmbH
• Shanghai Kehua Bio-Engineering Co Ltd
• Randox Laboratories Ltd
• Beijing Leadman Biochemistry Co Ltd
• Fujifilm Corp
• Mindray Medical International Ltd

第 15 章：策略建議

第16章 關於出版商,免責事項

Global Immunoturbidimetry Reagents Market was valued at USD 5.40 Billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 6.10% till 2030. Immunoturbidimetry reagents play a pivotal role in clinical diagnostics, particularly in the field of immunology. This specialized type of assay relies on the principle of turbidimetry, which measures the degree of turbidity or cloudiness in a solution. In immunoturbidimetry, this method is employed to quantitatively determine specific proteins or substances in a patient's blood sample. The process begins by introducing a patient's serum or plasma sample to a reagent containing antibodies specific to the target protein or analyte. If the target protein is present in the sample, it will bind with the antibodies, forming immune complexes. These complexes scatter light passing through the solution, resulting in an increase in turbidity. This change in turbidity is directly proportional to the concentration of the target analyte. Immunoturbidimetry reagents are crucial components of this process, as they contain the specific antibodies necessary for the formation of immune complexes.

These reagents are meticulously formulated to ensure high specificity and sensitivity, allowing for accurate quantification of the target protein. Moreover, they are designed to minimize interference from other substances in the sample, ensuring precise and reliable results. One of the key advantages of immunoturbidimetry is its wide applicability across a range of analytes, including proteins like C-reactive protein (CRP), immunoglobulins, and complement proteins. This makes it a versatile tool in clinical laboratories for assessing various disease states and monitoring patient health. Additionally, immunoturbidimetry assays are relatively rapid, providing timely results that are crucial for timely clinical decision-making. Furthermore, immunoturbidimetry is amenable to automation, allowing for high-throughput analysis of patient samples. This enhances the efficiency of clinical laboratories, enabling them to process a large volume of tests in a shorter timeframe. The automation of immunoturbidimetry also reduces the potential for human error, further ensuring the accuracy and reliability of results.

Key Market Drivers

Rising Prevalence of Chronic and Infectious Diseases

The increasing prevalence of chronic and infectious diseases is a significant driver propelling the expansion of the Global Immunoturbidimetry Reagents Market. As healthcare systems worldwide focus on early disease detection, monitoring, and effective management, the demand for high-precision diagnostic solutions such as immunoturbidimetry-based assays continue to rise. Chronic diseases, also known as non-communicable diseases (NCDs), have become the leading cause of mortality and morbidity worldwide. Conditions such as cardiovascular diseases (CVDs), diabetes, kidney diseases, autoimmune disorders, and cancer require continuous monitoring and early detection, creating a strong demand for accurate, reliable, and cost-effective diagnostic reagents like immunoturbidimetry reagents. According to a 2023 report by the World Heart Federation (WHF), global deaths from cardiovascular disease (CVD) surged from 12.1 million in 1990 to 20.5 million in 2021, reflecting a sharp increase in disease prevalence and associated risk factors. CVD remained the leading cause of death worldwide in 2021, with 80% of fatalities concentrated in low- and middle-income countries (LMICs). This trend underscores the urgent need for targeted healthcare investments, improved diagnostic capabilities, and scalable treatment solutions in these high-burden regions.

Biomarkers such as high-sensitivity C-reactive protein (hs-CRP), apolipoproteins (Apo A1 & Apo B), and fibrinogen are crucial for assessing cardiovascular risk and disease progression. Immunoturbidimetry reagents enable fast and cost-effective quantification of these biomarkers in routine clinical settings, increasing their adoption in diagnostic laboratories. By 2045, projections from the International Diabetes Federation (IDF) indicate that one in eight adults-approximately 783 million people-will be living with diabetes, marking a 46% increase from current levels. Notably, over 90% of cases will be type 2 diabetes, driven by a complex interplay of socioeconomic disparities, shifting demographics, environmental influences, and genetic predisposition. Regular monitoring of glycated hemoglobin (HbA1c) is essential for diabetes management. Immunoturbidimetry assays are widely used for HbA1c testing, offering a high-throughput, automated, and cost-effective solution.

The three most impactful pathogens were those responsible for tuberculosis (TB) at 65.1 million DALYs, malaria at 53.6 million, and HIV/AIDS at 52.1 million, highlighting their significant burden on global health. Notably, malaria parasites had the highest impact among children under five, contributing to 37.2 million DALYs, underscoring the urgent need for targeted interventions, improved access to treatment, and enhanced disease prevention strategies. The pandemic accelerated demand for immune response biomarkers such as ferritin, procalcitonin, D-dimer, and CRP, all of which can be analyzed using immunoturbidimetry reagents. Hospitals and diagnostic laboratories expanded their immunoturbidimetric testing capacities to monitor COVID-19-related complications, strengthening the market's growth trajectory. HIV/AIDS and hepatitis patients require frequent monitoring of immunoglobulins and inflammatory markers, both of which are efficiently measured using immunoturbidimetry-based assays. Tuberculosis remains a leading infectious disease, and the demand for serum protein analysis using immunoturbidimetry reagents has risen due to the need for accurate inflammation monitoring. Sepsis is a life-threatening condition requiring immediate detection of inflammatory biomarkers such as CRP, procalcitonin (PCT), and interleukin-6 (IL-6). Immunoturbidimetric tests provide fast and automated screening, enabling early intervention and reducing mortality rates.

Key Market Challenges

Low Adoption Rate of Automated Immunochemistry Products

The low adoption rate of automated immunochemistry products in developing economies presents a significant hindrance to the market's growth and advancement. While automated immunochemistry products offer numerous benefits, including enhanced efficiency, accuracy, and streamlined workflows, their uptake in these regions has been comparatively slow. One primary factor contributing to this challenge is the limited financial resources and budget constraints prevalent in many developing economies. The initial investment required for acquiring and implementing automated immunochemistry systems can be substantial, encompassing the cost of instrumentation, reagents, and the necessary infrastructure. In regions where healthcare budgets are constrained, prioritizing such investments can be a complex decision for healthcare facilities and institutions. Moreover, the maintenance and operational costs associated with automated immunochemistry systems may pose an ongoing financial burden for healthcare providers in these economies. This includes expenses related to instrument calibration, regular maintenance, and staff training. As a result, some healthcare facilities may be hesitant to make the transition from manual or semi-automated methods to fully automated immunochemistry platforms.

Key Market Trends

Rising Adoption of Automated and High-Throughput Diagnostic Systems

Automation is revolutionizing the clinical diagnostics industry, and immunoturbidimetry assays are increasingly being integrated into high-throughput laboratory analyzers. The demand for fast, accurate, and efficient testing solutions is leading to the widespread adoption of fully automated immunoassay platforms, which enhance diagnostic workflows and reduce human error.

Automated immunoturbidimetric systems can process a high volume of samples simultaneously, significantly reducing turnaround times and increasing laboratory productivity. Modern analyzers now incorporate artificial intelligence (AI) and machine learning (ML) algorithms to improve result accuracy, error detection, and predictive diagnostics. Automation ensures consistent and standardized immunoturbidimetric assay results, making it ideal for clinical laboratories, hospitals, and reference diagnostic centers. Hospitals and large diagnostic chains are investing in automated immunoturbidimetry analyzers to improve cost efficiency, reduce labor costs, and minimize reagent wastage. The integration of automated immunoturbidimetry systems with cloud-based data management and laboratory information systems (LIS) is expected to drive market growth by enabling seamless data sharing, remote monitoring, and enhanced laboratory efficiency.

Key Market Players

• Danaher Corporation
• Abbott Laboratories Inc
• Siemens Healthineers AG
• F. Hoffmann-La Roche AG
• DIALAB GmbH
• Shanghai Kehua Bio-Engineering Co Ltd
• Randox Laboratories Ltd
• Beijing Leadman Biochemistry Co Ltd
• Fujifilm Corp
• Mindray Medical International Ltd

Report Scope:

In this report, the Global Immunoturbidimetry Reagents Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Immunoturbidimetry Reagents Market, By Type:

• Common Immune Turbidimetric Reagent
• Latex Enhanced Immune Turbidimetric Reagent

Immunoturbidimetry Reagents Market, By Application:

• Glycated hemoglobin
• Retinol Binding Protein
• C-Reactive Protein
• Anti-streptococcal hemolysin "O"
• Rheumatoid Factor
• Other

Immunoturbidimetry Reagents Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Immunoturbidimetry Reagents Market.

Available Customizations:

Global Immunoturbidimetry Reagents Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Immunoturbidimetry Reagents Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Common Immune Turbidimetric Reagent, Latex Enhanced Immune Turbidimetric Reagent)
  • 5.2.2. By Application (Glycated hemoglobin, Retinol Binding Protein, C-Reactive Protein, Anti-streptococcal hemolysin "O", Rheumatoid Factor, Other)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Immunoturbidimetry Reagents Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Immunoturbidimetry Reagents Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Immunoturbidimetry Reagents Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Immunoturbidimetry Reagents Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application

7. Europe Immunoturbidimetry Reagents Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Immunoturbidimetry Reagents Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
  • 7.3.2. United Kingdom Immunoturbidimetry Reagents Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
  • 7.3.3. Italy Immunoturbidimetry Reagents Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
  • 7.3.4. France Immunoturbidimetry Reagents Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Immunoturbidimetry Reagents Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application

8. Asia-Pacific Immunoturbidimetry Reagents Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Immunoturbidimetry Reagents Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Immunoturbidimetry Reagents Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Immunoturbidimetry Reagents Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Immunoturbidimetry Reagents Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Immunoturbidimetry Reagents Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application

9. South America Immunoturbidimetry Reagents Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Immunoturbidimetry Reagents Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Immunoturbidimetry Reagents Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Immunoturbidimetry Reagents Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application

10. Middle East and Africa Immunoturbidimetry Reagents Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Immunoturbidimetry Reagents Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Immunoturbidimetry Reagents Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Immunoturbidimetry Reagents Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Immunoturbidimetry Reagents Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Danaher Corporation
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Abbott Laboratories Inc
• 14.3. Siemens Healthineers AG
• 14.4. F. Hoffmann-La Roche AG
• 14.5. DIALAB GmbH
• 14.6. Shanghai Kehua Bio-Engineering Co Ltd
• 14.7. Randox Laboratories Ltd
• 14.8. Beijing Leadman Biochemistry Co Ltd
• 14.9. Fujifilm Corp
• 14.10.Mindray Medical International Ltd

15. Strategic Recommendations

16. About Us & Disclaimer